Feb 27, 2024Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
Feb 01, 2024Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Dec 01, 2023Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement
Nov 29, 2023Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
Nov 28, 2023Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
Nov 12, 2023Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia
Nov 07, 2023Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
Oct 31, 2023Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3
